Tracer library / [90Y]Y-90-ITGA6B4

[90Y]Y-90-ITGA6B4

Also written as Y-90-ITGA6B4

Radionuclide: Y-90 t½ 3843.6 min
Modality: Therapy
Production route: —
Stage: —
Syntheses indexed: 2

Hepatobiliary and pancreatic cancer Preclinical only, no clinical indication yet

What it is

Compound class: Radiolabeled anti-integrin α6β4 monoclonal antibody (radioimmunoconjugate)
Target / mechanism: Targets integrin α6β4 (α6β4) overexpressed on tumor cells PMID 27246980
Clinical application: Radioimmunotherapy of pancreatic cancer xenografts PMID 27246980
Theranostic pair: —

Published syntheses

Module	Cassette	Purification	Yield %	RCP %	Precursor / supplier	Source
Manual synthesis	—	SPE	80	>95%	CHX-A''-DTPA-conjugated anti-α6β4 antibody…CHX-A''-DTPA-conjugated anti-α6β4 antibody (ITGA6B4) Macrocyclics	29204055 2017 World J Gastroenterol Human anti-α6β4 monoclonal antibody (IgG1) was labeled with beta-emitter 90Y, as previously reported[30]. - The radiochemical yield was approximately 80%
Manual synthesis	—	SPE	85 to 90%	>99%	CHX-A′′-DTPA Macrocyclics	27246980 2016 Oncotarget Human anti-α6β4 monoclonal antibody (IgG1) was labeled with 90Y, as previously reported - The radiochemical yield was approximately 85 to 90%

Precursor

Common precursor: —
Suppliers seen in the literature: —
Cited suppliers in indexed syntheses: Macrocyclics
Typical final purification: —

Need this precursor?We can point you to suppliers for [90Y]Y-90-ITGA6B4, or handle the enquiry for you.

Get in touch

Notes

Added at stage 21 from therapy-discovered.xlsx (bulk PubMed search by isotope/therapy-type/known-agent, not individually researched yet) -- 2 articles found. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 29204055: 'CHX-A''-DTPA-conjugated anti-α6β4 antibody (ITGA6B4)'.